Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3934/publichealth.2016.2.348 http://scihub22266oqcxt.onion/10.3934/publichealth.2016.2.348 C5690360!5690360!29546168     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       AIMS+Public+Health 2016 ; 3 (2): 348-56 Nephropedia Template TP {{tp|p=29546168|t=2016. Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL) |pdf=|usr=}}{{29546168}} gab.com Text Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL) JO: AIMS Public Health http://www.kidney.de/pget.php?&tw=1&pmid=29546168 #FOAvip The U.S. Food and Drug Administration issued a drug safety communication on 05/30/2013 recommending ?against prolonged use of magnesium sulfate to stop preterm labor (PTL) due to bone changes in exposed babies.? In September of 2013, The American Congress of Obstetrics and Gynecologists issued Committee Opinion No. 573 ? Magnesium Sulfate Use in Obstetrics? , which supports the short term use of MgSO4 to prolong pregnancy (up to 48 hrs.) to allow for the administration of antenatal corticosteroids.? Are these pronouncements by respected organizations short sighted and will potentially result in more harm than good? The FDA safety communication focuses on bone demineralization (a few cases with fractures) with prolonged administration of MgSO4 (beyond 5?7 days). It cites 18 case reports in the Adverse Event Reporting System with an average duration of magnesium exposure of 9.6 weeks (range 8?12 wks). Other epidemiologic studies showed transient changes in bone density which resolved in the short duration of follow up. Interestingly, the report fails to acknowledge the fact that these 18 fetuses were in danger of PTD and the pregnancy was prolonged by 9.6 weeks (e.g. extending 25 weeks to 34.6 wks), thus significantly reducing mortality and morbidity. Evidence does support the efficacy of MgSO4 as a tocolytic medication. The decision to use magnesium, the dosage to administer, the duration of use, and alternative therapies are physician judgments. These decisions should be made based on a reasonable assessment of the risks of the clinical situation (PTL) and the treatments available versus the benefits of significantly prolonging pregnancy. Twit Text FOAVip Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL) ????AIMS Public Health http://www.kidney.de/pget.php?&tw=1&pmid=29546168 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29546168 #FOAvip English Wikipedia <ref>{{Cite pmid|29546168}}</ref> Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL) #MMPMID29546168 Elliott JP; Morrison JC; Bofill JA AIMS Public Health 2016[]; 3 (2): 348-56 PMID29546168show ga The U.S. Food and Drug Administration issued a drug safety communication on 05/30/2013 recommending ?against prolonged use of magnesium sulfate to stop preterm labor (PTL) due to bone changes in exposed babies.? In September of 2013, The American Congress of Obstetrics and Gynecologists issued Committee Opinion No. 573 ? Magnesium Sulfate Use in Obstetrics? , which supports the short term use of MgSO4 to prolong pregnancy (up to 48 hrs.) to allow for the administration of antenatal corticosteroids.? Are these pronouncements by respected organizations short sighted and will potentially result in more harm than good? The FDA safety communication focuses on bone demineralization (a few cases with fractures) with prolonged administration of MgSO4 (beyond 5?7 days). It cites 18 case reports in the Adverse Event Reporting System with an average duration of magnesium exposure of 9.6 weeks (range 8?12 wks). Other epidemiologic studies showed transient changes in bone density which resolved in the short duration of follow up. Interestingly, the report fails to acknowledge the fact that these 18 fetuses were in danger of PTD and the pregnancy was prolonged by 9.6 weeks (e.g. extending 25 weeks to 34.6 wks), thus significantly reducing mortality and morbidity. Evidence does support the efficacy of MgSO4 as a tocolytic medication. The decision to use magnesium, the dosage to administer, the duration of use, and alternative therapies are physician judgments. These decisions should be made based on a reasonable assessment of the risks of the clinical situation (PTL) and the treatments available versus the benefits of significantly prolonging pregnancy. äRisks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PT(epmc).pdf DeepDyve Pubget Overpricing